Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd versus T-DM1 in high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy
2023-507961-24-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Trastuzumab deruxtecan with Kadcyla (2 arms). Primary endpoints: Invasive disease-free survival and IDFS by investigator assessment. Planned start Apr 2021; status: authorised.
02
Drugs
trastuzumab emtansinetrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-507961-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507961-24-00.